BMJ: Rethinking neoadjuvant chemotherapy for breast cancer

February 18, 2018

Full text download Neoadjuvant-chemotherapy-for-breast-cancer-BMJ-13-Jan-2018-p-66-68-print-and-online-versions-1.pdf

 

http://www.bmj.com/content/360/bmj.j5913

 

Key Messages

  • Neoadjuvant chemotherapy is being increasingly used for breast cancer despite higher rates of local recurrence and no evidence of survival benefit, mainly because of the immediate and dramatic pathological responses seen with newer drugs

  • The increased pathological response of the primary tumour does not translate into a survival benefit even when given in the adjuvant setting, challenging the paradigm of “window of opportunity” studies

  • We must acknowledge that neoadjuvant chemotherapy may not be beneficial to patients

  • We should consider reducing the widespread use of neoadjuvant chemotherapy

     

     

     

     

     

     

     

     

     

Share on Facebook
Share on Twitter
Please reload

King Edward VII's Consulting Rooms

Prof Vaidya's Breast Clinic timings:

 

Thursdays 9.30 am to 1pm

Other days by appointment

Secretary: Shona Brogan

L: 02070348890 M: 07306 444 066

shona@londonbreastcancer.com

King Edward the VII's Hospital,

Emmanuel Kaye House
37 Devonshire St, Marylebone,

London, W1G 6QA

The London Clinic

20 Devonshire Place

London W1G 6BW